Long-term survival in a patient with multiple metastatic gastric cancer treated with PTX plus emvolimab and disitamab vedotin: case report and treatment experience: A case report
Yongjin Zhou,Meifeng Zhang,Li Dai,Zhiqiang Yan,Haibin Wang,Hongxin Yang,Xiangren Jin,Qian Wang
DOI: https://doi.org/10.1097/md.0000000000036927
IF: 1.6
2024-01-20
Medicine
Abstract:Gastric cancer is a common malignant tumor worldwide, with a relatively poor prognosis and a serious threat to human health. According to the statistics of the International Agency for Research on Cancer, there will be about 1 million new cases of gastric cancer in the world in 2020, and about 800,000 deaths due to gastric cancer, ranking fifth in the incidence rate of malignant tumors and third in the mortality rate. [ 1 ] As the early symptoms of gastric cancer are not obvious and more than half of the affected Chinese population refuse gastroscopy, these patients are already in the progressive stage when they are diagnosed. The 5-year survival rate of patients with progressive gastric cancer is approximately 30% and the median survival period is less than a year. [ 2 ] Among the numerous organs affected by metastases, the peritoneum is one of the most common sites and one of the most complex and difficult medical challenges faced by clinicians. Patients with this type of combined multimetastatic gastric cancer have poor survival, with a 5-year survival rate of <10%. [ 3 ] The median survival is only 3.1 to 10.6 months, year survival is 16.0% to 40.7% [ 4 ] ; owing to its anatomical location, it is difficult for drugs to cross the peritoneal-plasma barrier, and this barrier limits the attainment of the effective concentrations of chemotherapeutic drugs in the peritoneal cavity. [ 5 ] Peritoneal metastases are found in 20% of patients with gastric cancer during the preoperative examination, and more than 50% of patients with stage T3 and T4 gastric cancer develop peritoneal metastases after radical gastric cancer surgery. The prognosis for these patients is extremely poor. [ 6 ] Therefore, the treatment of patients with peritoneal metastasis of gastric cancer is essential yet a challenge for clinicians. At present, the main treatment method for patients with advanced gastric cancer and multiple metastases is still systemic chemotherapy, and the median overall survival (OS) of patients receiving conventional chemotherapy is about 12 months. [ 7 ] Since the first targeted drug approved for gastric cancer, trastuzumab, was introduced, progress in the treatment of gastric cancer has stagnated for nearly a decade. In recent years, anti HER2 therapy and various biomarker targeted gastric cancer (GC) therapy have recently broken this trend. [ 8 ] For example, anti-programmed cell death 1 antibodies have demonstrated impressive efficacy and prolonged survival in untreated microsatellite instability high (MSI-H)/defective mismatch repair (dMMR) mGC patients. [ 9 ] Substantial breakthroughs in the treatment of gastric cancer have been achieved with novel anti-HER2 therapeutic agents, such as trastuzumab deruxtecan and disitamab vedotin. [ 10 ] In our patient, we followed the neoadjuvant intraperitoneal systemic chemotherapy (NIPS) treatment plan advocated by Prof Zhu Zhenggang from Shanghai Ruijin Hospital. With the release of disitamab vedotin, it indicates that HER2 positive gastric cancer patients and HER2 low expression gastric cancer patients have considerable antitumor efficacy and tolerable safety. This has given hope to patients with advanced gastric cancer treatment. Blocking angiogenesis is a key strategy in GC therapy, including anti-vascular endothelial growth factor (VEGF) monoclonal antibodies, VEGF-binding proteins, and VEGF receptor tyrosine kinase inhibitors. [ 11 ] Recent studies have confirmed that albumin-bound paclitaxel analogs can maintain high concentrations in the peritoneal cavity for a long time owing to their high molecular weights. In addition, after intravenous administration, the can effectively penetrate the peritoneal cavity and remain in the intraperitoneal cavity for up to 72 hours. [ 12 ] Programmed cell death 1 (PD-1) is a t cell surface receptor that inhibits immune responses when bound to its ligand (PDL1 or PD-L2), which is present in normal human cells and cancer cells. PD-1 is an immunotherapeutic drug such as the target of Envafolimab. One of their applications is in the treatment of MSI-H tumors, in which microsatellite sequences accumulate mutations due to dMMR. Through the comprehensive application of these new drugs and innovative treatment methods, we have achieved surprising therapeutic results for a gastric cancer patient with advanced multiple metastases.
medicine, general & internal